Philadelphia, PA - Olfactory Biosciences Corp. (OLFC) the makers of NOXO Autism Balm(TM) announce today the success of their innovative Autism balm. OLFC ‘s Chief Scientist Dr. V. Ruth Pinney and developer of NOXO Autism Balm(TM) offers a life changing solution that provides unprecedented hope for families isolated by behavioral issues related to sensitivities and overstimulation in children with Autism.
Dr. Pinney said that what makes NOXO’s Autism Balm(TM) unique is that it, "Is a simple, but powerful way to ‘tone down’ their overwhelming perceptions. The Autism Balm WORKS and works well with most children that have Autism Spectrum Disorders (ASD). It is successful because it targets sensitivities naturally, changing the child's perception to sensory inputs in a direct, safe way!" It works very well on its own or with other Autism Spectrum therapies as an adjunct. Autism Aid will also assist in supporting the child in eating a variety of nutritious foods.
NOXO Autism Balm is similar to a lip balm but is applied just below the nostrils on the upper lip. Allowing the natural formula to be inhaled and take effect.Parents and therapists administering NOXO’s Autism Balm(TM) report that it brings tranquility, calm and happiness to a child experiencing anxiety and displaying coping behaviors.
NOXO’s solution is safe, natural, easy to apply and non-invasive. It works on your body’s natural processes and responses. NOXO Autism Balm(TM) is now priced at $ 29.95 for 100 doses….about $ 1 a day and Amazon Guaranteed.You can get more information on NOXO Autism Aid™ at http://www.noxoinfo.com/autism.html
About Olfactory Biosciences Corp
Olfactory Biosciences Corp.’s NOXO division is focused to develop a variety of products targeting Olfactory Receptors for the desired effect. These alternative medicine wellness products may modify behavior or provide relief to common behavior challenges such as anxiety, smoking or weight control, as examples.
FORWARD-LOOKING STATEMENTS"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements by the Company, statements regarding the NOXO product line, optimism related to the business, expanding ales and other statements in this press release are forward-looking statements within the meaning of the Securities Litigation
Reform Act of 1995. Such statements are based on current expectations, estimates and projections about the Company's business. Words such as expects, anticipates, intends, plans, believes, sees, estimates and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve certain risks and uncertainties that are difficult to predict. Actual results could vary materially from the description contained herein due to many factors including continued market acceptance of the Company's products or the need to raise additional capital. In addition, actual results could vary materially based on changes or slower growth in the indoor garden market; the potential inability to realize expected benefits and synergies; domestic and
international business and economic conditions; changes in customer demand or ordering patterns; changes in the competitive environment including pricing pressures or technological changes; technological advances; shortages of manufacturing capacity; future production variables impacting excess inventory and other risk factors listed from time to time in the Company's Securities and Exchange Commission (SEC) filings under "risk factors" and elsewhere. The forward-looking statements contained in this press release speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release.
Richard Stevenson, President
Olfactory Biosciences Corp.
333 E. Lancaster Ave. Suite 317
Wynnewood, PA 19096, USA
Source: Olfactory Biosciences Corp.
- Autism Spectrum Disorders